Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Farmers Insurance
Cerilliant
Citi
Queensland Health
Mallinckrodt
Deloitte
Moodys
Colorcon

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,365,180

« Back to Dashboard

Which drugs does patent 6,365,180 protect, and when does it expire?


Patent 6,365,180 protects ZIPSOR and is included in one NDA. There has been one Paragraph IV challenge on Zipsor.

This patent has twenty-six patent family members in nineteen countries.

Summary for Patent: 6,365,180

Title: Oral liquid compositions
Abstract:The present invention relates to novel, liquid and semi-solid pharmaceutical compositions which can be administered in liquid form or can be used for preparing capsules containing such pharmaceutical compositions. Also provided are methods of using and processes for preparing the pharmaceutical compositions of the present invention.
Inventor(s): Meyer; Glenn A. (Wilmington, NC), Trespidi; Laura A. (89073 Ulm, DE), Wilson; Edward S. (Wilmington, NC), Clark; Christy M. (Southport, NC), Desai; Ashok J. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC)
Assignee:
Application Number:09/354,982
Patent Claim Types:
see list of patent claims
Composition; Use; Dosage form; Process; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Depomed Inc
ZIPSOR
diclofenac potassium
CAPSULE;ORAL022202-001Jun 16, 2009ABRXYesYes► Subscribe► SubscribeY NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,365,180

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,287,594 Oral liquid compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,365,180

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine80085► Subscribe
Slovakia572002► Subscribe
Slovenia20849► Subscribe
Russian Federation2252019► Subscribe
Norway20020208► Subscribe
Norway20003698► Subscribe
MexicoPA02000583► Subscribe
South Korea20020050223► Subscribe
Japan2003507415► Subscribe
Japan2002509103► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Teva
Merck
McKesson
Harvard Business School
Chinese Patent Office
Cerilliant
Boehringer Ingelheim
Healthtrust
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot